NysnoBio is focused on harnessing the therapeutic potential of the Parkin enzyme to address early onset Parkinson's disease (PD), particularly the prevalent autosomal recessive mutation that leads to a loss of function in this critical protein. The company is advancing a gene therapy pipeline aimed at delivering Parkin therapeutics to patients, with a specific focus on a one-time treatment that can reverse the progression of PD. Their approach involves a clinically validated adeno-associated virus (AAV) vector, which has a well-established safety profile and is capable of efficiently targeting multiple cell types. This innovative strategy is designed to protect and restore the health of dopamine neurons, which are crucial for motor function and are adversely affected in Parkinson's disease.

The scientific foundation of NysnoBio's technology lies in the role of Parkin in regulating mitochondrial health through a process known as mitophagy. Parkin facilitates the removal of damaged mitochondria, thereby preventing toxic oxidative stress and maintaining cellular energy balance. The absence of Parkin activity is linked to the degeneration of dopamine neurons, and NysnoBio aims to replace the lost Parkin protein to restore normal mitochondrial function. Their research is backed by a team of experts who have extensively studied the Parkin enzyme, including the founder who first published a high-resolution crystal structure of the enzyme, paving the way for the development of targeted therapeutics for patients suffering from Parkinson's disease.

United States

NysnoBio ia dedicated to developing the therapeutic potential of the Parkin protein for patients with serious medical conditions. We envision a future where the power of the Parkin pathway is directed toward specific disease areas, where the activation of the repair pathway can have maximum therapeutic benefits. Our core team of industry professionals and network of academic experts are working together to deliver on the scope of therapeutic potential for Parkin cellular repair.

NysnoBio

Company Details